Platelet rich plasma was removed and centrifuged at 1550 g for seven minutes. The platelet pellet was adjusted to a concentration of 300 · 10 6 platelets per mL, and 100 lL of this suspension was incubated for 15 min at 37°C with saturating concentrations of murine antihuman GPIIb/IIIa antibody (AMAC Inc, Westbrook, ME, USA), washed twice, and resuspended. Platelets were then incubated with FITC conjugated goat anti-mouse antibody (BD Biosciences, San Jose, CA, USA) for 15 min at room temperature, washed twice and analyzed on a FACS scan (BD Biosciences). Platelets were gated based on their forward and side scatter characteristics, and FITC mean fluorescence intensity was recorded using histogram plots.
Case 1
Patient 1 presented with prolonged bleeding after circumcision and both bleeding and bruising after immunizations. GT was diagnosed at age 22 months based on platelet aggregation studies, which revealed a pathognomonic pattern of normal aggregation to ristocetin but absent response to ADP, epinephrine, and collagen. Flow cytometry analysis at a research laboratory also found no evidence of fibrinogen receptor components, consistent with the diagnosis of Type I GT. He received only three platelet transfusions through age five yr but almost 20 platelet transfusions by age eight. He was hospitalized five times for bleeding from nasal and gastrointestinal mucosae, or into joints. AntiGPIIb/IIIa antibodies did not emerge but unrelated cord blood transplantation was considered given the recurrent life-threatening bleeds and two presentations with hemorrhagic shock. Cord blood was chosen over an adult volunteer donor given the excellent level of matching, the large cell dose, and the reduced potential for GVHD. Placement of a tunneled CVC for transplant was complicated by hypovolemic shock because of a massive hemothorax that was evacuated via a thoracotomy tube. Hemostasis was achieved using frequent platelet transfusions and rfVIIa 300 mcg/kg every six h for 24 h. Initiation of transplant conditioning was delayed for six days to allow for recovery and was well tolerated. Bilateral serosanguinous pleural effusions on D+7 required drainage over the subsequent two weeks through thoracotomy tubes placed again under the cover of rfVIIa and platelet transfusions. Although an etiology for the effusions was not established, an inflammatory or capillary leak response to the transplant conditioning regimen in the context of a resolving hemothorax was considered plausible because pleural fluid cultures remained negative, and absence of frank blood was inconsistent with the diagnosis of recurrent hemothorax. Platelets were transfused to maintain platelet counts above 20 000/lL or prevent bleeding. Transfusion frequency was increased as necessary around the time of invasive procedures. Neutrophil and platelet engraftment occurred on D+26 and D+48, without further bleeding episodes. Episodes of asymptomatic CMV reactivation on D+40 and D+167 were treated successfully with valganciclovir and CMV immune globulin. He did not develop GVHD, and tacrolimus was discontinued by D+250. At 45 months after transplant, he was a straight A student in middle school, growing normally and unrestricted in his activities with a Lansky performance score of 100%. He was taking only levothyroxine for hypothyroidism that developed 2.5 yr after transplant. The absence of recurrent bleeding episodes that followed recovery of normal platelet counts and full donor chimerism was an acceptable surrogate for normal platelet function. Formal platelet function studies or GPIIb/IIIa expression levels were not obtained.
Case 2
Patient 2 presented in infancy with petechial rashes, prolonged oozing from immunization sites, and bruising as his mobility increased. Platelet count and coagulation studies were normal, but Platelet GPIIb/IIIa expression was significantly reduced (Table 1 and Fig. 1 ). Subsequent recurrent mucosal bleeds included three life-threatening hemorrhages between ages 18 and 21 months that were managed with absorbable gelatin-compressed sponge packs, -aminocaproic acid, rfVIIa, transfused red cells, and platelets. By three years of age, platelet a b /L). CMV viremia on D+6 was treated with foscarnet and subsequently valganciclovir. Transient BK viruria with hematuria and frequent dysuria were treated with transfusions, phenazopyridine, and oxybutynin. The PICC line required replacement twice in the first two months (once for self-removal, once for thrombus and bacteremia), but otherwise was suitable for all intravenous needs. Mild Grade II GVHD of the stomach on D+51 was treated with prednisone and mycophenolate mofetil that were sequentially discontinued by D+265. At 344 days after transplant antiplatelet antibodies were absent. Platelet GPIIa/IIIb expression was normal (Fig. 1) . As there was no evidence of GVHD, a tacrolimus taper was begun. Now, 12 months post-HCT, he has no evidence of bleeding, normal blood counts, growth, and development, and a Lansky performance score of 100%.
Discussion
To our knowledge, this is the first report of cord blood transplantation for GT, and several practical considerations are worth comment. First, the risk of placing a tunneled CVC in patients who are refractory to platelet transfusions cannot be underestimated. At the time of CVC placement for the 14 reported patients, five fortunately remained responsive to platelet transfusions (1) (2) (3) (4) (5) (6) (7) (8) . Among the remaining nine patients, only four were clearly stated to be refractory to platelet transfusions, and rfVIIa was the mainstay for achieving hemostasis in this group (1, 6, 8, 9) . Bleeding in our Patient 2 had been only minimally responsive to rfVIIa. A near fatal hemorrhage associated with placement of a tunneled CVC in Patient 1, together with the knowledge of a similar incident in another patient, prompted us to select a PICC line for Patient 2 prior to conditioning. This PICC line was replaced twice post-transplant but otherwise allowed one potential iatrogenic risk for major pretransplant hemorrhage to be avoided.
Our next decision to administer pretransplant rituximab to Patient 2 attempted to abrogate antiplatelet antibodies. Rituxumab has been used to treat refractory ITP in children (10), and we were quite familiar with using standard 375 mg/m 2 doses of rituximab to treat refractory chronic GVHD and/or immune-mediated cytopenias after HCT (11, 12) . We reasoned that the risk to benefit ratio of a single dose of rituximab added to the conditioning regimen was likely to be favorable when faced with the known risks for delayed engraftment or non-engraftment of platelets after cord blood transplantation. There are no published data on rituximab being used for antibody desensitization before HCT. However, alloantibody desensitization protocols that include rituximab before renal transplantation have been successful in preventing antibodymediated renal allograft rejection (13, 14) although failure to completely eradicate alloantibodies may still occur because rituximab does not deplete plasma cells (13, 15) .
Intense cytotoxic conditioning appears to have controlled this problem in the small number of cases where platelet alloimmunization was present, but rituximab offers an additional and more targeted B cell approach to reducing alloantibodies. It is of interest that two reports included alemtuzumab with conditioning, which also achieves prolonged host B cell depletion (7, 8) . One patient who did not receive anti-B cell serotherapy developed anti-GPIIb/ IIIa antibodies on D+5 and became unresponsive to platelet transfusions but did respond to IVIG (6) .
Finally, the most common BMT conditioning for GT has been BUCY with or without fludarabine. Non-ablative conditioning in one case was associated with graft rejection (1). Reduced intensity conditioning followed by matched related peripheral blood graft resulted in stable 30% whole blood donor chimerism, which was evidently sufficient to correct the bleeding disorder (7). Our two cases suggest that targeted busulfan, cyclophosphamide (BUCY), and antithymocyte globulin can be effective for achieving durable cord blood engraftment and correction of bleeding in GT. Full restoration of platelet GPIIb/IIIa expression is not required to correct the bleeding disorder as demonstrated when siblings with intermediate GPIIb/IIIa expression were marrow donors (2, 3). Nonetheless, a normal unrelated donor is more likely to fully restore GPIIb/IIIa expression as shown by Patient 2 (Fig. 1) .
Our two cases provide proof of principle that cord blood can be an appropriate stem cell source for HCT after targeted BUCY conditioning for children with life-threatening GT.
